Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
BTIG Maintains Bullish View on Paratek Pharmaceuticals (PRTK) Following Ad Com Briefing Docs
August 6, 2018 2:05 PM EDTBTIG analyst Robert Hazlett reiterated a Buy rating and $56 price target on Paratek Pharmaceuticals (NASDAQ: PRTK) following FDA briefing documents for Omadacycline.
Hazlett commented, "In our view, there appears little concern regarding ABSSSI (skin) indication for Wednesdays upcoming FDA Ad Com for Omadacycline; we view a recommendation for Omadacyclines approval in ABSSSI as highly likely. The... More
